Double-Digit Growth Forecast for China’s Robotic Surgical Systems Market

China is experiencing a surge in the adoption of robotic systems across various healthcare domains. As the demand for advanced medical technologies continues to escalate, robotic systems are becoming integral to surgical procedures, diagnostic processes, and patient care.

Consequently, the country’s robotic surgical systems market is expected to grow 12% annually between 2023 and 2033, according to GlobalData. The company’s report, “Robotic Surgical Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033,” concludes that China accounted for roughly 30% of the Asia-Pacific (APAC) robotic surgical systems market last year.
 
Last fall, Johnson & Johnson received regulatory approval in China for its Monarch Platform and Monarch Bronchoscope, a robotically assisted device. The company claims the platform is the first minimally invasive, robotic-assisted technology approved for peripheral lung procedures in China and the first J&J MedTech robotic-assisted technology approved in the country. It also marked the first regulatory approval of the Monarch Platform outside of the United States.
 
“China’s rising mortality rates highlight the limitations of the currently available diagnostics, particularly their inability to effectively detect diseases like cancer in their early stages,” GlobalData Medical Devices Analyst Diksha Balmuchu said. “This emphasizes the urgent need for more advanced, less invasive, and precise interventions, prompting a shift towards robotic-assisted interventions.” 
 
Johnson & Johnson’s Monarch Platform enables physicians to reach small, hard-to-access peripheral lung nodules at an early stage and with greater precision. With its flexible robotic capabilities, it has the potential to improve patient outcomes and fulfill unmet clinical requirements.
 
“China continues to make steady progress in the research and healthcare domain, advancing towards the integration of robotic-assisted technology. Monarch, one such technology with its promising results, has the potential to alleviate diseases, reducing the risk of mortality and facilitating timely treatment in China. Further advancements could make it a valuable addition to conventional methods, enhancing accuracy and productivity,” Balmuchu concluded.